title: Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy.
abstract: Protein tyrosine phosphatase 1B (PTP1B) is an enzyme that downregulates the insulin receptor. Inhibition of PTP1B is expected to improve insulin action, and the design of small molecule PTP1B inhibitors to treat type II diabetes has received considerable attention. In this work, NMR-based screening identified a nonselective competitive inhibitor of PTP1B. A second site ligand was also identified by NMR-based screening and then linked to the catalytic site ligand by rational design. X-ray data confirmed that the inhibitor bound with the catalytic site in the native, "open" conformation. The final compound displayed excellent potency and good selectivity over many other phosphatases. The modular approach to drug design described in this work should be applicable for the design of potent and selective inhibitors of other therapeutically relevant protein tyrosine phosphatases.
authors.affiliation: Metabolic Disease Research, Global Pharmaceutical Research and Development Organization, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA. bruce.szczepankiewicz@abbott.com
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Szczepankiewicz
authors.forename: Gang
authors.initials: G
authors.lastname: Liu
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Hajduk
authors.forename: Cele
authors.initials: C
authors.lastname: Abad-Zapatero
authors.forename: Zhonghua
authors.initials: Z
authors.lastname: Pei
authors.forename: Zhili
authors.initials: Z
authors.lastname: Xin
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Lubben
authors.forename: James M
authors.initials: JM
authors.lastname: Trevillyan
authors.forename: Michael A
authors.initials: MA
authors.lastname: Stashko
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Ballaron
authors.forename: Heng
authors.initials: H
authors.lastname: Liang
authors.forename: Flora
authors.initials: F
authors.lastname: Huang
authors.forename: Charles W
authors.initials: CW
authors.lastname: Hutchins
authors.forename: Stephen W
authors.initials: SW
authors.lastname: Fesik
authors.forename: Michael R
authors.initials: MR
authors.lastname: Jirousek
mesh_terms: D000595:Amino Acid Sequence; D001665:Binding Sites; D001667:Binding, Competitive; D002384:Catalysis; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D007700:Kinetics; D008024:Ligands; D008958:Models, Molecular; D008969:Molecular Sequence Data; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods; D010072:Oxamic Acid / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*; D011487:Protein Conformation; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D004791:Enzyme Inhibitors; D008024:Ligands; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; D017027:Protein Tyrosine Phosphatases; D010072:Oxamic Acid